The Glucagon Paradox in Next-Generation Incretin Therapy: How GLP-1, GIP, and Glucagon Receptor Co-Agonism May Amplify Weight Loss Despite Glucagon’s Hyperglycemic Biology D. Mcauley Abstract The development of dual and triple incretin-based receptor agonists represents a major advance in the pharmacologic treatment of obesity, type
Tag: Type 2 diabetes
Ozempic Nation: Paradigm Shift or Public Health Mirage?
Ozempic Nation Paradigm Shift or Public Health Mirage Review Abstract The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies has transformed the management of obesity and type 2 diabetes mellitus. Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, initiated a major shift in
Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM): How Practice is Changing
Managing Diabetes in the Age of Continuous Glucose Monitoring (CGM) How Practice is Changing Review Abstract The integration of continuous glucose monitoring technology into diabetes management has significantly reshaped clinical practice over the past decade. Continuous glucose monitoring systems provide real time, dynamic assessment of interstitial glucose
Type 2 Diabetes Mellitus: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention
Type 2 Diabetes Mellitus as a Multifactorial Cardiometabolic Disease: Cellular Mechanisms, Reductionist Pitfalls, and Evidence-Based Prevention Narrative Review Abstract Type 2 diabetes mellitus (T2DM) is a progressive, heterogeneous, multi-organ metabolic disease characterized by chronic hyperglycemia arising from inadequate insulin secretion relative to metabolic demand, usually
Obesity as Chronic Disease: Building a Follow-up Model Like HTN/A1c
Obesity as Chronic Disease Building a Follow-up Model Like HTNA1c Abstract Obesity is increasingly recognized as a chronic, relapsing, multifactorial disease that requires long term clinical management rather than episodic intervention. Its pathophysiology involves complex interactions among genetic predisposition, neuroendocrine regulation, metabolic adaptation, environmental
Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs
Why GLP-1 Receptor Agonists Are Becoming Essential Cardiovascular Drugs Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a transformative class of medications in the management of type 2 diabetes, demonstrating an approximate 14 percent reduction in major adverse cardiovascular events. Initially developed
Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility
Glucagon-Like Peptide-1 Receptor Agonists and Human Fertility: Mechanisms, Evidence, and Clinical Implications Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established for the treatment of type 2 diabetes mellitus and obesity. Increasingly, reports suggest a possible association between GLP-1 RA use and
Is Type 2 Diabetes Reversible? New Research Challenges Medical Consensus
Is Type 2 Diabetes Reversible? New Research Challenges Medical Consensus Introduction The concept of type 2 diabetes reversibility represents a profound shift in the understanding and management of a condition long regarded as chronic and progressive. Diabetes remains a major global health burden, with prevalence
The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy?
The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy? Abstract The development of tirzepatide, a first in class dual glucose dependent insulinotropic polypeptide and glucagon like peptide 1 receptor agonist, represents a potentially transformative advance in the management of type 2 diabetes and obesity. By simultaneously targeting
Continuous Glucose Monitoring (CGM) for Type 2 Diabetes: Should It Be the Standard?
